Alpha 2.0
Login Register
» Articles » PMID: 23561999

Turning a Blind Eye to Deferasirox's Toxicity?

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 2013 Apr 9
PMID 23561999
Citations 7
Authors
G J Kontoghiorghes
Affiliations
Soon will be listed here.
Citing Articles

Deferasirox-induced iron depletion promotes BclxL downregulation and death of proximal tubular cells.

Martin-Sanchez D, Gallegos-Villalobos A, Fontecha-Barriuso M, Carrasco S, Sanchez-Nino M, Lopez-Hernandez F Sci Rep. 2017; 7:41510.

PMID: 28139717 PMC: 5282523. DOI: 10.1038/srep41510.

New developments and controversies in iron metabolism and iron chelation therapy.

Kontoghiorghe C, Kontoghiorghes G World J Methodol. 2016; 6(1):1-19.

PMID: 27019793 PMC: 4804243. DOI: 10.5662/wjm.v6.i1.1.

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.

Kontoghiorghe C, Kontoghiorghes G Drug Des Devel Ther. 2016; 10:465-81.

PMID: 26893541 PMC: 4745840. DOI: 10.2147/DDDT.S79458.

World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.

Kontoghiorghe C, Andreou N, Constantinou K, Kontoghiorghes G World J Methodol. 2014; 4(3):163-88.

PMID: 25332915 PMC: 4202455. DOI: 10.5662/wjm.v4.i3.163.

Deferasirox nephrotoxicity-the knowns and unknowns.

Diaz-Garcia J, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Nino M, Villarrubia J, Ortiz A Nat Rev Nephrol. 2014; 10(10):574-86.

PMID: 25048549 DOI: 10.1038/nrneph.2014.121.